There is increasing interest in exosomes as a new modality for drug discovery, as they are a drug delivery system inherent to living organisms. Exosomes contain various bioactive substances derived from cells (microRNAs, proteins, etc.), which they deliver to target cells. However, exosomes of biological origin are highly diverse. To use exosomes as drugs, those with the desired properties must be isolated and purified—the difficulty of isolating and purifying exosomes has become a barrier to drug discovery. Since its start-up in 2019, EXORPHIA has conducted independent research to develop the INPACT-EV™ platform technology to purify and concentrate exosomes and characterize them. By repeating the manufacturing process over numerous cycles under various conditions, we identified the optimal conditions and successfully obtained the desired exosomes in purified form without compromising their activity. With this proprietary technology as a foundation, we are establishing a collaborative framework with researchers in the academic world best suited to specific diseases to create drug development pipelines that target diseases for which there are high unmet medical needs.
